Odronextamab Is Active With Acceptable Benefit–Risk Profile in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma


December 6, 2020 - Odronextamab, is a novel CD20xCD3 bispecific antibody, continues to show intriguing antitumor activity and an acceptable safety profile in patients with relapsed/refractory B-cell non-Hodgkin lymphoma, including those who have previously received chimeric antigen receptor T-cell therapy.

Rajat Bannerji, MD, PhD

Odronextamab (REGN1979), is a novel CD20xCD3 bispecific antibody, continues to show intriguing antitumor activity and an acceptable safety profile in patients with relapsed/refractory B-cell non-Hodgkin lymphoma (NHL), including those who have previously received chimeric antigen receptor (CAR) T-cell therapy, according to longer follow-up of a phase 1 study presented at the 2020 ASH Annual Meeting & Exposition.1

Data showed that in patients who previously received CAR T-cell therapy (n = 24), a particularly difficult-to-treat population, the objective response rate (ORR) was 33% and the complete response (CR) rate was 21%. CRs appeared durable, with 100% of CRs still ongoing; 1 patient has maintained a CR for 20 months, which is still ongoing, lead study author Rajat Bannerji, MD, PhD, a hematologist/Oncologist, and chief of Hematologic Malignancies at Rutgers Cancer Institute of New Jersey, said in a virtual presentation during the meeting.

“Odronextamab is a novel CD20 x CD3 bispecific antibody which offers an off-the-shelf, primarily outpatient treatment option for patients with relapsed/refractory B-NHL,” Bannerji said. “In this first-in-human phase 1 trial, odronextamab has demonstrated compelling antitumor activity, including durable complete responses in heavily pretreated patients with follicular lymphoma and DLBCL.”

In patients with relapsed/refractory DLBCL who had not previously received CAR T-cell therapy (n = 11), the ORR was 55%, all of which were CRs. Eighty-three percent of CRs were durable and 1 patient remains in an ongoing CR with 21 months of follow-up.

Additionally, in those with relapsed/refractory follicular lymphoma (n = 30), the ORR was 90% and the CR rate was 70%. The CRs appeared to be durable (81%), and the median duration of CR was not reached.

Results also showed that the agent had an acceptable benefit–risk profile, with grade 3 being the highest grade for cytokine release syndrome (CRS) and was mostly transient, occurring with initial or intermediate step-up doses. Additionally, odronextamab was administered up to 320 mg weekly without dose-limiting toxicities (DLTs) or reaching the maximum-tolerated dose (MTD).

Odronextamab is an off-the-shelf, CD20 x CD3 bispecific antibody that binds to CD3 on T cells and CD20 on malignant B cells, which triggers T-cell–mediated cytotoxicity independent of T-cell receptor recognition. The agent is administered intravenously in the outpatient setting.

At the 2019 ASH Annual Meeting, earlier findings of the phase 1 findings of odronextamab showed preliminary signs of safety and efficacy in this patient population.2 The dose-escalation portion of the trial is now complete, Bannerji explained.

In the phase 1 study, dexamethasone is given as premedication, followed by split and step-up doses of odronextamab, which are used to mitigate the risk for CRS during weeks 1 and 2 of treatment. Odronextamab is given weekly for 12 weeks and then continued every 2 weeks until disease progression or study discontinuation. Investigators assessed for response every 12 weeks, according to Lugano criteria.

To be eligible for enrollment, patients had to have CD20-positive relapsed/refractory B-cell NHL, had prior treatment with an anti-CD20 antibody, an ECOG performance status of 0 to 1, and adequate organ function.

The primary end points are safety, tolerability, and DLTs; key secondary end points included antitumor activity, pharmacokinetics, and the recommended phase 2 dose.

The median age was 67.0 years (range, 27-89), 70.6% of patients were male, and the ECOG performance status was 1 in 58.1% of patients. A total 86.8% of patients had an Ann Arbor stage III to IV disease, and 33.8% of patients had bulky disease.

Patients had B-cell NHL, which comprised diffuse large B-cell lymphoma (DLBCL; 57.4%), grade 1-3a follicular lymphoma (27.9%), mantle cell lymphoma (8.8%), marginal zone lymphoma (4.4%), and other (1.5%). The median number of prior lines of therapy was 3 (range, 1-11), and 7.4% of patients underwent prior autologous stem cell transplant and 25.7% had previously received CAR T-cell therapy. Most patients (80.1%) were refractory to their most recent line of therapy, 83.1% to an anti-CD20 antibody, and 67.6% to an alkylator therapy. A total 66.9% of patients were double refractory to an alkylator and an anti-CD20 antibody.

Of the 136 patients enrolled on the study to date, treatment is ongoing in 7 (5.1%) and the study is ongoing for 24 patients. Of the patients who discontinued treatment (72.8%), reasons included disease progression (36.8%), death (14.0%), patient or physician decision/withdrawal of consent (11.0%), other (9.6%), adverse event (AE; 0.7%), and missing data (0.7%). Thirteen patients have completed the trial.

Regarding safety, 92.6% of all treatment-emergent AEs (TEAEs) were treatment-related; 44.9% of all serious TEAEs were related to therapy. The treatment-related mortality rate was 3.7%, which Bannerji said was in line with other studies of relapsed lymphomas.

The most frequent grade 3 or higher TEAEs occurring in at least 10% of patients included anemia (24.3%; grade 1-3 at baseline in 22%), lymphopenia (20.6%; transient), neutropenia (18.4%; febrile, 2.2%), and hypophosphatemia (18.4%; transient). Nine patients discontinued therapy because of TEAEs, which included cytomegalovirus infection (grade 1; n = 1), fatigue (grade 1; n = 1), pneumonia (grade 2; n = 2); hemolysis, fatigue pneumonia, toxoplasmosis, and tumor lysis syndrome (grade 3; n = 1 each); as well as abscess (n = 1), which was unrelated to the study drug.

No patients discontinued odronextamab due to CRS or neurotoxicity; overall, 5.9% of patients had a TEAE that led to treatment discontinuation. Additionally, no dose-dependent increases in toxicity were observed.

CRS occurred in 61% of patients, at grade 1 (35.3%), grade 2 (18.4%), grade 3 (6.6%), and grade 4 (0.7%). The majority of CRS events were mild or moderate in severity, and the majority of the grade 3 or higher CRS events occurred with initial or intermediate step-up doses of odronextamab. Specifically in patients with follicular lymphoma or DLBCL, the highest grade of CRS was grade 3 (n = 1 follicular lymphoma). The CRS events did resolve within a median of 2 days (range, 1-41) with supportive care measures.

Regarding AEs of special interest, no grade 3 or higher TLS events were reported in either patients with follicular lymphoma or DLBCL; 2 grade 3 or higher TLS events were observed in other patients with B-cell NHL, but they were confined to initial and intermediate odronextamab step-up doses. Moreover, the highest grade of an ICANS-like event that was reported was grade 3 and occurred infrequently, and no patients discontinued odronextamab due to ICANS-like events.

An ongoing international phase 2 trial (NCT03888105) is evaluating the efficacy and safety of odronextamab in patients with relapsed/refractory B-cell lymphoma. Additional studies are planned to evaluate chemotherapy-free combinations with odronextamab, and those with chemotherapy in earlier lines of treatment.


  1. Bannerji R, Allan JN, Arnason JE, et al. Odronextamab (REGN1979) , a human CD20 x Cd3 bispecific antibody, induces durable, complete responses in patients with highly refractory B-cell non-Hodgkin lymphoma, including patients refractory to CAR T therapy. Presented at: 2020 ASH Annual Meeting and Exposition; December 4-8, 2020; virtual. Abstract 400.
  2. Bannerji R, Allan JN, Arnason JE, et al. Clinical activity of REGN1979, a bispecific human, anti-CD20 x anti-CD3 antibody, in patients with relapsed/refractory (R/R) B-cell non-Hodgkin lymphoma (B-NHL). Blood. 2019;134(suppl_1). doi:10.1182/blood-2019-122451.s
Related Videos
J. Andrew Livingston, MD, on Forging Forward With Novel Sarcoma Trials
Thomas McCauley, PhD, on Potential Advantages of Epigenetic Therapy Over Small Molecule, Gene Therapy
Fiona Freeman, PhD, on Investigating miRNA-29b in Osteosarcoma Models
Paul Harmatz, MD, on Challenges With Assessing Neurocognitive Outcomes
Related Content
© 2023 MJH Life Sciences

All rights reserved.